462 related articles for article (PubMed ID: 34224740)
1. BNT162b2 Messenger RNA COVID-19 Vaccine Effectiveness in Patients With Inflammatory Bowel Disease: Preliminary Real-World Data During Mass Vaccination Campaign.
Ben-Tov A; Banon T; Chodick G; Kariv R; Assa A; Gazit S;
Gastroenterology; 2021 Nov; 161(5):1715-1717.e1. PubMed ID: 34224740
[No Abstract] [Full Text] [Related]
2. Effect of Pfizer/BioNTech and Oxford/AstraZeneca vaccines against COVID-19 morbidity and mortality in real-world settings at countrywide vaccination campaign in Saudi Arabia.
Meo SA; Fahad Al-Jassir F; Al-Qahtani S; Albarrak R; Usmani AM; Klonoff DC
Eur Rev Med Pharmacol Sci; 2021 Nov; 25(22):7185-7191. PubMed ID: 34859883
[TBL] [Abstract][Full Text] [Related]
3. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study.
Haas EJ; McLaughlin JM; Khan F; Angulo FJ; Anis E; Lipsitch M; Singer SR; Mircus G; Brooks N; Smaja M; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet Infect Dis; 2022 Mar; 22(3):357-366. PubMed ID: 34562375
[TBL] [Abstract][Full Text] [Related]
4. Association Between BNT162b2 Vaccination and Incidence of SARS-CoV-2 Infection in Pregnant Women.
Goldshtein I; Nevo D; Steinberg DM; Rotem RS; Gorfine M; Chodick G; Segal Y
JAMA; 2021 Aug; 326(8):728-735. PubMed ID: 34251417
[TBL] [Abstract][Full Text] [Related]
5. Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients.
Amit S; Regev-Yochay G; Afek A; Kreiss Y; Leshem E
Lancet; 2021 Mar; 397(10277):875-877. PubMed ID: 33610193
[No Abstract] [Full Text] [Related]
6. Signals of hope: gauging the impact of a rapid national vaccination campaign.
Shilo S; Rossman H; Segal E
Nat Rev Immunol; 2021 Apr; 21(4):198-199. PubMed ID: 33712744
[TBL] [Abstract][Full Text] [Related]
7. How many lives do COVID vaccines save? Evidence from Israel.
Arbel R; Moore CM; Sergienko R; Pliskin J
Am J Infect Control; 2022 Mar; 50(3):258-261. PubMed ID: 34971714
[TBL] [Abstract][Full Text] [Related]
8. BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar.
Tang P; Hasan MR; Chemaitelly H; Yassine HM; Benslimane FM; Al Khatib HA; AlMukdad S; Coyle P; Ayoub HH; Al Kanaani Z; Al Kuwari E; Jeremijenko A; Kaleeckal AH; Latif AN; Shaik RM; Abdul Rahim HF; Nasrallah GK; Al Kuwari MG; Al Romaihi HE; Butt AA; Al-Thani MH; Al Khal A; Bertollini R; Abu-Raddad LJ
Nat Med; 2021 Dec; 27(12):2136-2143. PubMed ID: 34728831
[TBL] [Abstract][Full Text] [Related]
9. COVID-19 Vaccination Is Safe and Effective in Patients With Inflammatory Bowel Disease: Analysis of a Large Multi-institutional Research Network in the United States.
Hadi YB; Thakkar S; Shah-Khan SM; Hutson W; Sarwari A; Singh S
Gastroenterology; 2021 Oct; 161(4):1336-1339.e3. PubMed ID: 34144044
[No Abstract] [Full Text] [Related]
10. Viral loads of Delta-variant SARS-CoV-2 breakthrough infections after vaccination and booster with BNT162b2.
Levine-Tiefenbrun M; Yelin I; Alapi H; Katz R; Herzel E; Kuint J; Chodick G; Gazit S; Patalon T; Kishony R
Nat Med; 2021 Dec; 27(12):2108-2110. PubMed ID: 34728830
[TBL] [Abstract][Full Text] [Related]
11. Assessment of Effectiveness of 1 Dose of BNT162b2 Vaccine for SARS-CoV-2 Infection 13 to 24 Days After Immunization.
Chodick G; Tene L; Patalon T; Gazit S; Ben Tov A; Cohen D; Muhsen K
JAMA Netw Open; 2021 Jun; 4(6):e2115985. PubMed ID: 34097044
[TBL] [Abstract][Full Text] [Related]
12. Real-world safety data for the Pfizer BNT162b2 SARS-CoV-2 vaccine, historical cohort study' by Shasha et al.
Scorza FA; Finsterer J
Clin Microbiol Infect; 2022 Mar; 28(3):452-453. PubMed ID: 34839005
[No Abstract] [Full Text] [Related]
13. Real-world evidence for the effectiveness and breakthrough of BNT162b2 mRNA COVID-19 vaccine at a medical center in Japan.
Naito T; Yan Y; Tabe Y; Seyama K; Deshpande GA
Hum Vaccin Immunother; 2022 Dec; 18(1):1-2. PubMed ID: 34614387
[TBL] [Abstract][Full Text] [Related]
14. Blunting COVID-19's negative impact: Lessons from Israel's vaccination campaign.
Tsigaris P; Teixeira da Silva JA
Travel Med Infect Dis; 2021; 41():102029. PubMed ID: 33737163
[No Abstract] [Full Text] [Related]
15. Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization.
Khehra N; Padda I; Jaferi U; Atwal H; Narain S; Parmar MS
AAPS PharmSciTech; 2021 Jun; 22(5):172. PubMed ID: 34100150
[TBL] [Abstract][Full Text] [Related]
16. Association Between Exposure Characteristics and the Risk for COVID-19 Infection Among Health Care Workers With and Without BNT162b2 Vaccination.
Oster Y; Benenson S; Yochi Harpaz L; Buda I; Nir-Paz R; Strahilevitz J; Cohen MJ
JAMA Netw Open; 2021 Sep; 4(9):e2125394. PubMed ID: 34468758
[TBL] [Abstract][Full Text] [Related]
17. Israel's high case plateau may offer worrisome portent.
Wadman M
Science; 2021 Sep; 373(6562):1428-1429. PubMed ID: 34554791
[No Abstract] [Full Text] [Related]
18. Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis.
Yau K; Abe KT; Naimark D; Oliver MJ; Perl J; Leis JA; Bolotin S; Tran V; Mullin SI; Shadowitz E; Gonzalez A; Sukovic T; Garnham-Takaoka J; de Launay KQ; Takaoka A; Straus SE; McGeer AJ; Chan CT; Colwill K; Gingras AC; Hladunewich MA
JAMA Netw Open; 2021 Sep; 4(9):e2123622. PubMed ID: 34473256
[TBL] [Abstract][Full Text] [Related]
19. Immediate reactions after mRNA SARS-CoV-2 vaccination.
Jeimy S; Wong T; Song C
CMAJ; 2021 Dec; 193(48):E1842. PubMed ID: 34772737
[No Abstract] [Full Text] [Related]
20. Effects of BNT162b2 Covid-19 Vaccine Booster in Long-Term Care Facilities in Israel.
Muhsen K; Maimon N; Mizrahi A; Varticovschi B; Bodenheimer O; Gelbshtein U; Grotto I; Cohen D; Dagan R
N Engl J Med; 2022 Jan; 386(4):399-401. PubMed ID: 34936758
[No Abstract] [Full Text] [Related]
[Next] [New Search]
